Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
5.10
Nov 18 • 3:59 PM ET Dollar change-0.55 Percentage change(-9.73%)
Aftermarket Close
5.10
Aftermarket • 5:06 PM ET Dollar change+0.00 Percentage change(0.05%)
Index
-
Market Cap
13.30M
Enterprise Value
19.19M
Income
-26.02M
Sales
2.53M
Book/sh
3.97
Cash/sh
5.75
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
23
IPO
Feb 05, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
5.26
P/B
1.28
P/C
0.89
P/FCF
-
EV/EBITDA
-
EV/Sales
7.58
Quick Ratio
2.05
Current Ratio
2.05
Debt/Eq
2.44
LT Debt/Eq
2.06
Option/Short
No / Yes
EPS (ttm)
-14.97
EPS next Y
-9.20
EPS next Q
-5.82
EPS this Y
-5.55%
EPS next Y
51.17%
EPS next 5Y
48.35%
EPS past 3/5Y
27.67% 11.84%
Sales past 3/5Y
10.33% 101.61%
EPS Y/Y TTM
32.80%
Sales Y/Y TTM
-51.28%
EPS Q/Q
39.57%
Sales Q/Q
-100.00%
Insider Own
14.93%
Insider Trans
20.29%
Inst Own
41.13%
Inst Trans
-
ROA
-51.70%
ROE
-127.96%
ROIC
-99.23%
Gross Margin
72.54%
Oper. Margin
-1007.59%
Profit Margin
-1027.93%
SMA20
-16.90%
SMA50
7.87%
SMA200
13.55%
Trades
Shs Outstand
2.15M
Shs Float
-
52W High
7.78 -34.45%
52W Low
3.10 64.52%
Volatility
6.20% 8.01%
ATR (14)
0.46
RSI (14)
42.49
Beta
0.84
Rel Volume
0.41
Avg Volume
252.30K
Volume
102,895
Perf Week
-18.53%
Perf Month
18.33%
Perf Quarter
59.38%
Perf Half Y
10.63%
Perf YTD
-6.73%
Perf Year
10.51%
Perf 3Y
-73.02%
Perf 5Y
-97.11%
Perf 10Y
-
Prev Close
5.65
Price
5.10
Change %
-9.73%
Consensus
Buy
Avg. Price Target
$48.50
Implied Upside
+851.0%
Analysts6incl. previous ratings
Rating Distribution5 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
May 29, 2026Initiated
RRodman & Renshaw
Buy$22+331.4%
Oct 20, 2025Resumed
HH.C. Wainwright
Buy$7+37.3%
Jan 06, 2022Downgrade
MS logoMMorgan Stanley
Overweight → Equal-Weight
Mar 02, 2021Initiated
SSVB Leerink
Outperform$36+605.9%
Mar 02, 2021Initiated
SF logoSStifel
Buy$40+684.3%
Mar 02, 2021Initiated
MS logoMMorgan Stanley
Overweight$45+782.4%
Mar 02, 2021Initiated
GGuggenheim
Buy$42+723.5%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Coastlands Capital LP10% OwnerNov 16 '26Buy5.8933,094194,924495,510Nov 17 08:42 PM
Coastlands Capital LP10% OwnerNov 17 '26Buy5.7520,000114,998515,510Nov 17 08:42 PM
Coastlands Capital LP10% OwnerNov 09 '26Buy6.3850,000319,000462,416Nov 10 02:57 PM
Yonehiro GrantChief Operating OfficerSep 18 '26Sale3.246,85022,16917,269Sep 21 06:05 PM
Yonehiro GrantChief Operating OfficerSep 17 '26Sale3.324,90916,29024,119Sep 21 06:05 PM
Yonehiro GrantChief Operating OfficerSep 16 '26Sale3.771,4175,34829,028Sep 21 06:05 PM
Nemec SarahSenior VP, Finance and PAOJun 05 '26Buy3.885091,9731,924Sep 21 06:04 PM
Nemec SarahSenior VP, Finance and PAOSep 18 '26Sale3.244,07713,19517,082Sep 21 06:04 PM
Nemec SarahSenior VP, Finance and PAOSep 17 '26Sale3.322,9229,69621,159Sep 21 06:04 PM
Nemec SarahSenior VP, Finance and PAOSep 16 '26Sale3.778433,18124,081Sep 21 06:04 PM
Quinn William P.President, CEO and CFOJun 05 '26Buy3.886372,4692,950Sep 21 06:03 PM
Quinn William P.President, CEO and CFOSep 18 '26Sale3.249,13229,55525,384Sep 21 06:03 PM
Quinn William P.President, CEO and CFOSep 17 '26Sale3.326,54521,71834,516Sep 21 06:03 PM
Quinn William P.President, CEO and CFOSep 16 '26Sale3.771,8897,12941,061Sep 21 06:03 PM
Quinn William P.President, CEO and CFODec 05 '25Buy4.611255762,313Feb 04 04:32 PM
Nemec SarahSenior VP, Finance and PAODec 05 '25Buy4.611255761,415Feb 04 04:32 PM
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
Co-Founder & DirectorDr. Sheila K. Gujrathi M.D.
Founder & Strategic Scientific AdvisorDr. Miguel Sanjuan Ph.D.
Chief Scientific OfficerDr. Ryan Sullivan Ph.D.
Vice President of Corporate DevelopmentChristina Trout
Chief Medical OfficerMr. Hector Ortega M.D.